Lung Cancer | Specialty

The Next Steps in RET Inhibitor Research

October 18th 2019

Using RET Inhibitors in Clinical Practice

October 18th 2019

RET Inhibitor Trial Updates at ASCO and ESMO

October 18th 2019

How BLU-667 Has Changed the Treatment Landscape

October 18th 2019

ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019

LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019

LIBRETTO-001 Regimen Overview

October 18th 2019

RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019

The Importance of NGS Testing

October 18th 2019

RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019

RET Fusion, Point Mutation, and Signaling

October 18th 2019

Why RET Alteration is an Attractive Target for Therapy

October 18th 2019

Examining PD-L1 and TMB as Biomarkers of Immunotherapy Response in NSCLC

October 17th 2019

James G. Herman, MD, discusses the work that has been done to elucidate biomarkers of response to immunotherapy in non–small cell lung cancer and the necessity of molecular testing at diagnosis.

PACIFIC Trial Paves Way for More Immunotherapy Advances in Stage III NSCLC

October 17th 2019

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer.

Dr. Kerrigan on Design and Findings of the PROFILE 1001 Trial in ROS1-Mutated NSCLC

October 15th 2019

Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses the design and findings of the ongoing phase I PROFILE 1001 trial with crizotinib (Xalkori) in ROS1-mutated non–small cell lung cancer (NSCLC).

Groundbreaking Lung Cancer Research Abounds at Huntsman Cancer Institute and Intermountain Healthcare

October 14th 2019

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

Data Mine Demonstrates Heredity of Lung Cancers

October 12th 2019

Lisa A. Cannon-Albright, PhD, discusses her research regarding the heredity of lung cancer, histologic subgroups at increased risk, and the implications these data have on practice.

Dr. Kim on the KEYNOTE-189 Trial in Metastatic NSCLC

October 12th 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Molecular Testing for NSCLC Rapidly Evolves to Include More Markers

October 11th 2019

Kristen Champion, PhD, FACMG, discusses various molecular testing methods being used in non–small cell lung cancer.